Posted by AGORACOM
at 9:40 AM on Wednesday, April 21st, 2021
Durango Resources Inc.(TSXV:DGO) (Frankfurt-86A1) (OTC:ATOXF), (the “Company” or “Durango”) reports that further to the news of April 1, 2021, Durango has applied for drill permits on its wholly owned Discovery property.
The Discovery Property is 6,700ha in size and covers an important geological NE-SW regional structure which continues towards Troilus. The Property has great road access from the Route du Nord and is easily accessible due to the unusually warm spring weather conditions. Durango has applied for 15 exploration drill holes on the Discovery property for the 2021 exploration season.
Durango’s technical team is in the process of preparing an exploration program for the Discovery Property in June 2021, after it completes its exploration program at Windfall Lake and will announce the plans in more detail as they become available.
Durango CEO, Marcy Kiesman, stated, “Durango’s previous grab samples returned up to 7 g/t gold at surface on the Discovery property in a quartz vein in basalt. We look forward to receiving our permits so we can conduct follow up work on the Discovery property this summer.”
The technical contents of this press release were approved by George Yordanov, professional geologist, an Independent Qualified Person as defined by National Instrument 43-101. The Discovery Property has not yet been subject to an NI-43-101 report.
Discovery (Découverte), Québec
Durango owns 100% interest in the Discovery claims, which are adjacent Osisko Mining Inc. (TSX-OSK) and are 60km away from Troilus Gold Inc.’s past producing mine. The claims are located 100km away from Chibougamau, Québec in the Frotet Evans greenstone belt with year-round road access from the Route Nord. The 6,700-hectare property is compelling due to the structurally important south dipping synclinal fold nose deformed by a northwest fault zone and northeast structures.
Posted by AGORACOM
at 9:17 AM on Wednesday, April 21st, 2021
Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) (“Red Light Holland” or the “Company“), an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, is pleased to provide an update on the distribution of its iMicrodose Packs in the Netherlands.
“Over the last few months, we have continued executing on our goal to increase both the availability of our products and our brand’s visibility. iMicrodose Packs powered by Red Light Holland are now available in 144% more locations than previously announced. Relationships held by our wholly owned distribution company SR Wholesale, already, account for 13 new locations, demonstrating some of the synergies that we strategically planned to realize from the recently closed acquisition,” said Todd Shapiro, CEO and Director of Red Light Holland. “With over $31 million of cash and cash equivalents remaining on our balance sheet, we look forward to continuing to conservatively deploy capital into growth opportunities that support our long-term business objectives, while SR-Wholesale continues to do a major sales push across the Netherlands. We have a clear plan to get Red Light Holland products into many more retail stores hopefully for the summer market, while also concentrating on growing our online sales at www.iMicrodose.nl. As I’ve said in the past, we’re proud to be providing access now and we continue to deliver on that mandate.”
About Red Light Holland Corp.
The Company is an Ontario-based corporation engaged in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles to the legal market within the Netherlands, in accordance with the highest standards, in compliance with all applicable laws.
Posted by AGORACOM
at 9:11 AM on Wednesday, April 21st, 2021
Brookville Capital Intelligence Report Covers Treaty Creek Partners
The Brookville Capital Intelligence Report is a weekly newsletter out of London that covers the commodities markets. It tells subscribers about a wide variety of companies and has delivered some very strong returns. For example it told subscribers about Chalice when it was 15.5 cents and today it’s over $6.
Commodity TV is a channel focused on mining companies, experts, analysts and professional opinions of funds managers and more. Their video presentation of Treaty Creek can be found by clicking through the button below.
Fundamental Research Corp is one of the largest independent research houses in the world, with a 17-year track record of covering 550+ companies. As of April 05, 2021, FRC’s top picks were up 69.3% on average since initiation of coverage. Last week they initiated coverage on our JV Partner Tudor Gold / Treaty Creek.
The comprehensive report mention on Commodity TV can be accessed on their website by subscribing to their free membership.
EVEN, EVEN MORE COVERAGE: Stansberry Research, one of the largest investment research firms in the United States, had initiated coverage of Tudor Gold / Treaty Creek last year and issued an update on April 7th, 2021. This article can be accessed by subscribing to the Gold & Silver Report at Stansberry Research.
Posted by AGORACOM
at 8:21 AM on Wednesday, April 21st, 2021
XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce that it has entered into an agreement (the “Agreement”) with an established German pharmaceutical wholesaler and service provider (the “Distributor”) for the distribution, storage and logistics of XPhyto’s diagnostic products in Germany. The Agreement secures XPhyto a full-service distribution partner for its 25-minute SARS-CoV-2 (COVID-19) RT-PCR test system (“Covid-ID Lab”). Covid-ID Lab is registered within the European Union as a commercial in vitro diagnostic (CE-IVD) test.
Pursuant to the Agreement, the Distributor will distribute, store and deliver Covid-ID Lab test kits according to the product specifications and all applicable regulations to XPhyto’s customers. In addition, the Distributor will provide the documentation and fulfillment of storage obligations, the fulfillment of reporting and notification obligations, and the processing of any returned products. The obligations and services to be rendered under the Agreement satisfy all of the logistical and regulatory requirements for the commercial sale of COVID-ID Lab in Germany.
“With this agreement, we have secured a strong partner with an established medical distribution network throughout Germany. This is an exciting and critical step towards commercial sales of COVID-ID Lab,” said Hugh Rogers, CEO and Director of XPhyto. “The Company’s commercialization strategy is focused on the German market for initial product launch and the creation of robust and sustainable sales.”
Covid-ID Lab is a multiplex viral RNA probe kit based on the reverse transcriptase-polymerase chain reaction (RT-PCR) method. Covid-ID Lab requires only a single 20-minute PCR thermal cycle for assay performance without prior RNA extraction as part of the sample preparation. Many widely available standard PCR instruments are suitable to run the test. Results are collected after the PCR cycle via easy-to-read optical indicator strips on a simple fluidics platform. The elimination of RNA extraction for sample preparation reduces cross-contamination risk and minimizes the need for lab materials and trained personnel. The rapid results, minimal laboratory equipment, and ease of use are expected to translate into reduced operating costs, greater convenience and portability.
XPhyto is currently in discussions with various potential customers, distribution and wholesale partners as well as potential licensees. The sales launch in Europe is targeted for April 2021. The Company will provide further information and updates in due course.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.
About XPhyto Therapeutics Corp.
XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
Posted by AGORACOM
at 2:35 PM on Tuesday, April 20th, 2021
British Columbia government selects Maitri as provincial HealthTech leader; Virtual event designed to open doors, facilitate partnerships, expand business
VANCOUVER, BC , April 20, 2021 /CNW/ – Maitri Health Technologies Corp. (” Maitri “) (CSE: MTEC) (FRA: D84), a global platform for healthcare supply security, today announced it has been asked by the British Columbia Ministry of Jobs, Economic Recovery & Innovation to join a government-supported virtual trade mission to the United Kingdom.
The virtual trade mission will showcase an exclusive group of innovative B.C. HealthTech companies which are expanding business and development in the U.K., the world’s fifth largest economy.
“We’re honoured to be selected by B.C. Trade and Invest to represent B.C. HealthTech leadership,” said Andrew Morton , CEO of Maitri. “A government-supported trade mission can help opens doors, make connections and accelerate our existing European efforts to expand awareness and drive sales.”
“The timing is also opportune to help a market in transition. The U.K. is ramping up vaccinations but still fighting the long-term spread of COVID-19. Our digital strategy is to help protect people today with data intelligence and transition into to a fully functioning economy. Our goal is to provide a safe return to workplaces with long-term security that they stay open,” said Morton.
The trade mission, scheduled for April 26-30 , will be delivered in association with GTM Global and Vita Healthcare Solutions. B.C. Trade and Invest, which chose just 15 companies to participate, helps provincial companies access the U.K. markets and facilitate new partnerships.
Posted by AGORACOM
at 8:47 AM on Tuesday, April 20th, 2021
Mountain Valley MD Holdings Inc.(the “Company” or “MVMD“) (CSE: MVMD) (FRA:20MP) (OTCQB: MVMDF) is pleased to announce that it is proceeding with the application for the listing of its shares for trading on the TSX Venture Exchange (“TSXV”). The Company’s board of directors has approved the move and the Company intends to submit an application to the TSXV this week.
“We believe that pursuing a listing on the TSX-V is a great step for Mountain Valley MD Holdings Inc. and will provide increased liquidity and trading capabilities in MVMD’s common shares for both institutional and retail investors,” stated Dennis Hancock, President and CEO of Mountain Valley MD. “This is a significant part of our efforts to broaden our appeal to a larger shareholder base and continue to raise the Company’s profile among the North American investment community.”
Completion of the listing on the TSXV is subject to the satisfaction of listing requirements and the approval of the TSXV. In the meantime, MVMD’s shares will continue to trade on the Canadian Securities Exchange under the ticker symbol “MVMD”. Further updates will be provided as they become available.
ABOUT MOUNTAIN VALLEY MD HOLDINGS INC Mountain Valley MD is building a world-class biotech and life sciences company organization centred around the implementation of its patented Quicksome™ oral drug formulation and delivery technologies and its Quicksol™ solubilization technology for macrocyclic lactones, to innovate industry leading products that are sought out globally.
MVMD’s proposition for delivering Quicksome™ formulations that have rapid onset, high bioavailability, low variability and precision dosing is core to the Company’s success across key health and wellness categories. Consistent with its vision towards “Helping People Live Their Best Life”, MVMD applies its Quicksome™ and Quicksol™ technologies to its ground-breaking work for advanced delivery of vaccines and pharmaceutical drugs as well as the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and more.
The Company’s patented Quicksome™ desiccation technology utilizes advanced liposomes and other stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats that are consumed orally. The result is a new generation of product formulations that are capable of delivering vaccines, drugs and nutraceuticals into the body faster, with greater impact, efficiency and accuracy.
Posted by AGORACOM
at 8:12 AM on Tuesday, April 20th, 2021
Mr. Wolfgang Probst appointed as the Chief Operations Officer (COO) of XPhyto
Addition of Mr. Manfred Buchberger as the Head of Corporate Development
XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce the appointment of Mr. Wolfgang Probst as the Chief Operations Officer (COO) of XPhyto and the addition of Mr. Manfred Buchberger as the Head of Corporate Development at XP Diagnostics GmbH (“XP Diagnostics”), a wholly owned German subsidiary of the Company. With European CE-IVD approval announced March 18, 2021, for the Company’s lead diagnostic product, Covid-ID Lab, XPhyto continues to enhance its commercial team as it anticipates near-term distribution and sales.
Mr. Probst is an experienced management and finance consultant with expertise in mergers and acquisitions, corporate re-organizations, and divestitures. He has a proven track record of leadership, strategic planning, and organizational restructuring having guided multiple startups from inception to financial success. Mr. Probst was responsible for successfully structuring XPhyto’s European operations and establishing associated partnerships and collaborations, both commercial and academic. As the newly appointed COO of XPhyto, Mr. Probst will be responsible for managing the Company’s global operations. Mr. Probst will remain a director of XPhyto and the managing director of XP Diagnostics.
Mr. Buchberger is a global leader in the medical diagnostics industry. For almost a decade, he was the CEO and a member of the Global Management Board of a major European medical diagnostics and analytics company with annual revenues of over 600 million Euro. His addition to the Company brings decades of diagnostics industry experience focused on international business development, sales, marketing, and product management. Mr. Buchberger has successfully created, implemented, and managed business growth strategies across Europe, North and South America, Middle East and Asia, including the successful launch of new medical diagnostic products.
On March 18, 2021, XPhyto announced European commercial approval of Covid-ID Lab, a rapid 25-minute point-of-care PCR test for COVID-19. Mr. Probst and Mr. Buchberger will be responsible for executing the global product launch and businesses development of Covid-ID Lab.
Covid-ID Lab is a multiplex viral RNA probe kit based on the reverse transcriptase-polymerase chain reaction (RT-PCR) method. Covid-ID Lab requires only a single 20-minute PCR thermal cycle for assay performance without prior RNA extraction as part of the sample preparation. Many widely available standard PCR instruments are suitable to run the test. Results are collected after the PCR cycle via easy-to-read optical indicator strips on a simple fluidics platform. The elimination of RNA extraction for sample preparation reduces cross-contamination risk and minimizes the need for lab materials and trained personnel. The rapid results, minimal laboratory equipment, and ease of use are expected to translate into reduced operating costs, greater convenience and portability.
Posted by AGORACOM
at 10:54 AM on Monday, April 19th, 2021
Company’s common shares will begin trading on the OTCQB® Venture Market (“OTCQB”) today, April 19, 2021 under the current stock symbol “DTMXF”
Marshall Gunter, CEO of Datametrex AI Limited, “With the Company’s shares now quoted on the OTCQB, it will enhance our visibility and make the Company’s shares available to a much larger group of U.S. investors. “
Toronto, Ontario–(Newsfile Corp. – April 19, 2021) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTCQB: DTMXF) (the “Company” or “Datametrex”) is pleased to announce that after a successful application process for the OTCQB® Venture Market (“OTCQB”), the Company’s common shares will begin trading on the OTCQB today, April 19, 2021, at the opening of the market under the current stock symbol “DTMXF” and will remain listed on the TSX Venture Exchange under the ticker symbol “DM”.
Existing U.S. shareholders of Datametrex AI Limited shares, previously quoted on the OTC® Pink Open Market, will now be quoted on the OTCQB without any further action needed.
Marshall Gunter, CEO of Datametrex AI Limited, “With the Company’s shares now quoted on the OTCQB, it will enhance our visibility and make the Company’s shares available to a much larger group of U.S. investors. The quotation on the OTCQB is anticipated to enhance liquidity by providing current and prospective investors with an easily accessible and transparent trading platform where they go and obtain Real Time quotes and market information.”
About OTCQB
The OTCQB® Venture Market is the premier marketplace for entrepreneurial and development stage US and international companies that are committed to providing a high-quality trading and information experience for their US investors. To be eligible, companies must be current in their financial reporting, pass a minimum bid price test, and undergo an annual company verification and management certification process. The OTCQB quality standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors. The ability to have the Company’s shares electronically transferred between brokerages in the US is significantly more convenient and reduces the costs incurred in trading shares. When shares are able to trade electronically, existing investors benefit from greater liquidity and execution speeds, while opening the door to new investors that may have been previously restricted from the Company’s shares.
Posted by AGORACOM
at 10:39 AM on Monday, April 19th, 2021
George Scorsis, WeedMD’s CEO and Executive Chair, is scheduled to participate at The Planet MicroCap Showcase Virtual Event and Prohibition Partners LIVE
TORONTO, April 19, 2021 (GLOBE NEWSWIRE) — WeedMD Inc. (TSX-V:WMD) (OTCQX:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical-grade cannabis, is pleased to announce that George Scorsis, WeedMD’s CEO and Executive Chair, is scheduled to participate in the following upcoming investor events.
Planet MicroCap Showcase Virtual Panel – The Global Cannabis Industry in 2021
The Planet MicroCap Showcase Virtual Event brings together the most promising companies and the top dealmakers in MicroCap Finance for three (3) days of company presentations, 1:1 meetings and educational panels in the premier virtual event in MicroCap finance.
Prohibition Partners LIVE 2021 Global Virtual Cannabis Conference
Prohibition Partners LIVE is a global virtual cannabis conference and has seen 500+ industry-leading speakers, hosted agenda-defining content, and welcomed thousands of attendees from every continent. Prohibition Partners LIVE provides entrepreneurs, investors, and operators the edge in this rapidly moving market.
For more information or to schedule a one-on-one meeting with WeedMD, please contact KCSA Strategic Communications at [email protected] or the event organizers directly.
Posted by AGORACOM
at 9:55 AM on Monday, April 19th, 2021
VANCOUVER, BC / ACCESSWIRE / April 19, 2021 / Victory Square Technologies Inc. (“Victory Square” or the “Company”) (CSE:VST)(OTCQX:VSQTF)(FWB:6F6), a company that provides investors access to a diverse portfolio of next generation internet companies in key sectors including: digital health, gaming, blockchain, AR/VR, cybersecurity, and cloud computing, today announced that it will be presenting at the Planet MicroCap Showcase: VIRTUAL on Thursday, April 22 at 2:30 PM EST.
Chief Executive Officer, Shafin Diamond Tejani and CGO Vahid Shababi will be hosting the presentation and answering questions from investors.
To access the live presentation, please use the following information:
